Abstract:The differential expression of the desired gene product in the target tissue is central for gene therapy. One approach is to use a tissue-specific promoter to drive therapeutic gene expression. UroplakinII (UPII) is a urothelium-specific membrane protein. To investigate the feasibility of targeting gene therapy for bladder cancer, a DNA fragment of 2542-bp upstream of the UPII gene was amplified by PCR and linked to a promoterless firefly luciferase reporter gene. The transient transfection showed that the DNA fragment resulted in preferential expression in bladder carcinoma cells, with negligible expression in nonurothelium cells. Furthermore, the DNA segment located between −2545 and −1608 decided the tissue-specificity of the UPII promoter, the segment located between −328 and −4 being the core promoter of UPII. We generated two recombinant adenoviruses under the control of the UPII promoter: Ad-hUPII-GFP, carrying green fluorescence protein (GFP), and Ad-hUPII-TNF, carrying the tumor necrosis factor alpha (TNF α ). ELISA revealed that the secretion of TNF α by Ad-hUPII-TNF-infected bladder cancer cells was significantly higher than Ad-hUPII-TNF-infected nonurothelium cells. The conditioned medium from Ad-hUPII-TNF-infected bladder cancer cells apparently inhibited the proliferation of L929 cells, a TNF α -sensitive cell line, comparing to Ad-hUPII-TNF-infected nonurothelium cells. Intravesical inoculation with Ad-hUPII-TNF inhibited tumor growth in the orthotopic human bladder cancer model. The sustained high level of TNF α in urine was identified with ELISA. Taken together, these data suggest that most of the cis elements that confer the bladder-specificity and differentiation-dependent expression of the human UPII gene reside in the 2542-bp sequence, and TNF α driven by the human UPII (hUPII) promoter is effective in the specific inhibition of bladder cancer growth both in vivo and in vitro . These results may yield a new therapeutic approach for bladder cancer and provide information on the molecular regulation of urothelial growth, differentiation, and disease.

Construction of Urothelium-Specific Recombinant Adenovirus and Its Inhibition in Bladder Cancer Cell

Study on Inhibitation of the Tube Formation by RNA Introduced by Adenovirus by its Interference With and Decrease of VEGF Transcription

Antitumor Effects of Bladder Cancer-Specific Adenovirus Carrying E1A-androgen Receptor in Bladder Cancer

Biodistribution and Safety Assessment of Bladder Cancer Specific Recombinant Oncolytic Adenovirus in Subcutaneous Xenografts Tumor Model in Nude Mice.

Cloning and analysis of human UroplakinII promoter and its application for gene therapy in bladder cancer

AB087. the Biotherapy for Bladder Cancer

The Construction and Characterization of a Novel Adenovirus Vector of Artificial Microrna Targeting EGFR.

Targeting Gene Expression of the Mouse Uroplakin II Promoter to Human Bladder Cells

Prostate stem cell antigen enhancer and uroplakin II promoter based bladder cancer targeted tissue-specific vector.

[Effect of Mouse Uroplakin II Promoter on Human Bladder Cancer Cell Line].

A Novel Bladder Cancer - Specific Oncolytic Adenovirus by CD46 and Its Effect Combined with Cisplatin Against Cancer Cells of CAR Negative Expression

Construction of recombinant lentivirus vector containing retinoic acid-induced gene G and its effect on human lung cancer A549 cell line

Raav9-Upii-tk-egfp Can Precisely Transduce a Suicide Gene and Inhibit the Growth of Bladder Tumors.

Lentivirus-mediated p21/Waf-1 short hairpin RNA enhances the cytotoxic effects and replicative potential of a bladder cancer-specific oncolytic adenovirus in vitro.

Tumor-suppressing Effect of Recombinant Adenovirus Encoding LRIG1 Gene Driven by Survivin Promoter in Nude Mice Heterotransplanted Models of Human Bladder Cancer

Effect of Combined Treatment of Radiation and Tissue-Specific Recombinant Oncolytic Adenovirus on Bladder Cancer Cells

Enhanced antitumor efficacy of integrin-targeted oncolytic adenovirus AxdAdB3-F/RGD on bladder cancer

Fiber-modified Adenovirus-Mediated Suicide Gene Therapy Can Efficiently Eliminate Bladder Cancer Cells in Vitro and in Vivo

Synergistic Effect of Bladder Cancer-Specific Oncolytic Adenovirus in Combination with Chemotherapy.

Construction of the recombinant adenovirus vector with eGFR antisense cDNA of controlling cell cycle

Ex Vivo Organoid Model of Adenovirus-Cre Mediated Gene Deletions in Mouse Urothelial Cells